Vestor Capital LLC Decreases Stake in Pfizer Inc. $PFE

Vestor Capital LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 73.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,811 shares of the biopharmaceutical company’s stock after selling 7,915 shares during the period. Vestor Capital LLC’s holdings in Pfizer were worth $68,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in PFE. Brighton Jones LLC grew its stake in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Brookwood Investment Group LLC purchased a new stake in Pfizer in the 1st quarter worth approximately $227,000. Avantax Advisory Services Inc. grew its position in shares of Pfizer by 5.9% in the 1st quarter. Avantax Advisory Services Inc. now owns 369,411 shares of the biopharmaceutical company’s stock worth $9,361,000 after buying an additional 20,421 shares during the last quarter. Finally, HB Wealth Management LLC increased its stake in shares of Pfizer by 25.7% during the first quarter. HB Wealth Management LLC now owns 249,328 shares of the biopharmaceutical company’s stock valued at $6,318,000 after buying an additional 50,968 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. UBS Group reaffirmed a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Finally, Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.28.

Pfizer Trading Up 2.5%

Shares of NYSE PFE opened at $25.02 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a 50-day moving average of $24.84 and a 200 day moving average of $24.50. The stock has a market cap of $142.26 billion, a P/E ratio of 13.31, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.